| Size | Price | |
|---|---|---|
| 1mg | ||
| 5mg | ||
| 10mg | ||
| Other Sizes |
| Targets |
SARS-CoV-2, RSV[1][2]
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers that influence measurement during the drug development process. It's possible that the pharmacokinetics and functional range of medications contribute to the concern over mutagenesis [1]. Potential benefits of compounds with delayed generation include: (1) compounds with delayed generation may be able to extend the compound's pharmacokinetic characteristics, which could extend the compound's safety, tolerability, and improved tolerance; and (2) compounds with delayed generation may expand intestinal bioavailability. Deuterated compounds may be able to lessen the amount of first-pass metabolism required in the colon and intestinal wall, which would enable a higher percentage of the medicine to reach high bioavailability levels, which dictate its efficacy at low doses and better tolerability. (3) Enhance the properties of metabolism. Drug safety, drug metabolism (4), and hazardous or reactive metabolite reduction are all potential benefits of metabolites. Deuterated chemicals are harmless and have the potential to lessen or completely eradicate the negative effects of medicinal drugs. (5) Preserve medicinal qualities. According to earlier research, deuterated molecules should maintain a biochemistry similar to that of comparable hydrogen compounds.
|
| ln Vivo |
VV116 (25, 50 and 100 mg/kg; PO; bid for 4 days) exhibits a stronger activity and decreases the virus titers below the detection limit at 50 mg/kg, also reduces lung injury after RSV infection[1]. VV116 ( 25, 50 and 100 mg/kg; PO; single dosage) exhibits favorable PK properties and good safety profile[1]. Pharmacokinetic Parameters of VV116 (JT001) in Balb/c mice[1]. PO (25 mg/kg) PO (50 mg/kg) PO (100 mg/kg) Tmax (h) 0.42 ± 0.14 0.42 ± 0.14 0.42 ± 0.14 Cmax (ng/mL) 5360 ± 560 11617 ± 3443 24017 ± 6521 AUC0-t (ng/mL·h ) 11461 ± 1013 24594 ± 1059 47799 ± 6545 AUC0-∞ (ng/mL·h) 11534 ± 992 24739 ± 1028 48014 ± 6696 MRT0-∞ (ng/mL·h) 2.25 ± 0.32 2.15 ± 0.26 2.2 8 ± 0.53 Tmax ( h) 2.30 ± 1.10 3.27 ± 1.92 4.25 ± 0.53 Animal Model: Balb/c mice[1] Dosage: 25, 50 and 100 mg/kg Administration: PO; single dosage (Pharmacokinetics Analysis) Result: Exhibited favorable PK properties and good safety profile. Animal Model: Balb/c mice (6-8 weeks; intranasally infected with 4 × 10^6 FFU of RSV)[1] Dosage: 25, 50 and 100 mg/kg Administration: PO; bid for 4 days Result: Exhibited a stronger activity and decreased the virus titers below the detection limit at 50 mg/kg, also reduced lung injury after RSV infection.
|
| Cell Assay |
Cell viability assay
Cell Types: A549 (infected with RSV) [1] Tested Concentrations: 0-1000 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibited RSV replication in A549 cells, EC50 is 1.20±0.32 μM and CC50 is 95.92. ± 9.27 μM, selectivity index (SI) 80. |
| References |
[1]. Zhang R, et al. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct Target Ther. 2022;7(1):123. Published 2022 Apr 16.
[2]. Qian HJ, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects [published online ahead of print, 2022 Mar 16]. Acta Pharmacol Sin. 2022;1-9. |
| Molecular Formula |
C24H31DBRN5O7
|
|---|---|
| Molecular Weight |
583.45
|
| Exact Mass |
502.23
|
| Elemental Analysis |
C, 49.41; H, 5.70; Br, 13.69; N, 12.00; O, 19.19
|
| CAS # |
2779498-79-0
|
| Appearance |
Solid powder
|
| Synonyms |
VV116; VV 116; VV-116; JT001; JT-001; JT 001; Deuremidevir; Deuremidevir HBr; Deuremidevir hydrobromide; mindeudesivir; [GS621763; GS-621763; GS 621763]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (428.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7139 mL | 8.5697 mL | 17.1394 mL | |
| 5 mM | 0.3428 mL | 1.7139 mL | 3.4279 mL | |
| 10 mM | 0.1714 mL | 0.8570 mL | 1.7139 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
